Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Oncology Biosimilars market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.9% during the forecast period.
This report presents the market size and development trends by detailing the Oncology Biosimilars market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Oncology Biosimilars market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Oncology Biosimilars industry and will help you to build a panoramic view of the industrial development.
Oncology Biosimilars Market, By Type:
mAb
Immunomodulators
Hematopoietic Agents
G-CSF
Others
Oncology Biosimilars Market, By Application:
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
Some of the leading players are as follows:
Celltrion
Intas Pharmaceuticals
Teva Pharmaceutical Industries Ltd
BIOCAD
Dr Reddy’s Laboratories
Sandoz International
Biocon
Apotex
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Oncology Biosimilars Market: Technology Type Analysis
-
4.1 Oncology Biosimilars Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Oncology Biosimilars Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 mAb
4.3.2 Immunomodulators
4.3.3 Hematopoietic Agents
4.3.4 G-CSF
4.3.5 Others
5 Oncology Biosimilars Market: Product Analysis
-
5.1 Oncology Biosimilars Product Market Share Analysis, 2018 & 2026
-
5.2 Oncology Biosimilars Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Oncology Biosimilars Market: Application Analysis
-
6.1 Oncology Biosimilars Application Market Share Analysis, 2018 & 2026
-
6.2 Oncology Biosimilars Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Retail Pharmacies
6.3.2 Hospital Pharmacy
6.3.3 Online Pharmacy
7 Oncology Biosimilars Market: Regional Analysis
-
7.1 Oncology Biosimilars Regional Market Share Analysis, 2018 & 2026
-
7.2 Oncology Biosimilars Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Celltrion
9.1.1 Celltrion Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Intas Pharmaceuticals
9.2.1 Intas Pharmaceuticals Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Teva Pharmaceutical Industries Ltd
9.3.1 Teva Pharmaceutical Industries Ltd Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 BIOCAD
9.4.1 BIOCAD Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Dr Reddy’s Laboratories
9.5.1 Dr Reddy’s Laboratories Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Sandoz International
9.6.1 Sandoz International Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Biocon
9.7.1 Biocon Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Apotex
9.8.1 Apotex Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Dr. Reddy’s Laboratories
9.9.1 Dr. Reddy’s Laboratories Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 STADA Arzneimittel AG
9.10.1 STADA Arzneimittel AG Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
The List of Tables and Figures (Totals 110 Figures and 154 Tables)
Figure mAb Oncology Biosimilars market, 2015 - 2026 (USD Million)
Figure Immunomodulators Oncology Biosimilars market, 2015 - 2026 (USD Million)
Figure Hematopoietic Agents Oncology Biosimilars market, 2015 - 2026 (USD Million)
Figure G-CSF Oncology Biosimilars market, 2015 - 2026 (USD Million)
Figure Others Oncology Biosimilars market, 2015 - 2026 (USD Million)
Figure Retail Pharmacies market, 2015 - 2026 (USD Million)
Figure Hospital Pharmacy market, 2015 - 2026 (USD Million)
Figure Online Pharmacy market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Oncology Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table North America Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table North America Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table North America Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Canada Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Canada Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Europe Oncology Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table Europe Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Europe Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Europe Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Germany Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Germany Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table France Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table France Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Italy Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Italy Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Spain Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Spain Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Oncology Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table China Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table China Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Japan Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Japan Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table India Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table India Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Oncology Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table MEA Oncology Biosimilars market, by country, 2015 - 2026 (USD Million)
-
Table MEA Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table MEA Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table MEA Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Oncology Biosimilars market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Oncology Biosimilars market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Oncology Biosimilars market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Celltrion Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Intas Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Teva Pharmaceutical Industries Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table BIOCAD Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dr Reddy’s Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sandoz International Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biocon Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Apotex Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dr. Reddy’s Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table STADA Arzneimittel AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
